Tesamorelin has an FDA-approved HIV lipodystrophy indication, but not for longevity, ordinary weight loss, cognition, bodybuilding, or anti-aging.
A buyer guide to UFC GYM's PWR Clinics announcement, gym-based longevity medicine, and what to verify before buying GLP-1, TRT, peptide, IV, or recovery programs.
Retatrutide is promising in obesity trials, but products sold as retatrutide outside trials have triggered liver-toxicity warnings. Here is how clinic buyers can separate legitimate care from grey-market peptide risk.
The public follistatin and klotho study is a completed, industry-sponsored early-phase trial with 14 participants and no posted results. Here is what that means before paying for treatment.
ER-100 has entered a Phase 1 eye-disease trial. This is a safety milestone for partial epigenetic reprogramming, not approval or proof of whole-body age reversal.
A conservative 2026 guide to exosome therapy longevity clinic offers: evidence, FDA/EU regulation, costs, red flags, and safer alternatives.
A patient-safety guide to longevity clinic governance: medical accountability, evidence labels, diagnostics, AI, biomarkers, records, adverse events, and conflicts.
A buyer guide to IV NAD+, IV NR, oral NR and NMN that separates biochemical effects from unproven longevity outcomes and checks sterile-compounding risks.
GLP-1 microdosing longevity clinics in 2026 need scrutiny: see evidence, healthy-lean caveats, product-quality risks, and buyer red flags.
IV nutrient therapy can be clinically useful for selected deficiencies, but anti-aging claims are weaker. Here is how to compare clinics, costs, and safety protocols.
VO2 max is one of the better-supported longevity metrics, but the value depends on testing quality, medical screening, and a plan after the number.
Longevity clinics are usually regulated through doctors, medicines, devices, diagnostics, premises, and advertising claims — not as one universal clinic category.
What the FDA's July meeting did and did not change for BPC-157, TB-500, MOTS-c, Semax, Epitalon and other peptides marketed by longevity clinics.
WLC withdrew its 2026 peptide-clinic ranking because provider flags, marketing sources, dose tables, prices, and a claimed FDA reclassification did not support a safe recommendation.
An HHS announcement prompted reports of a peptide reclassification. Later FDA records show why an announcement, compounding policy, drug approval, and clinical evidence are different questions.
WLC withdrew its 2026 stem-cell clinic ranking because the evidence did not support recommendations, prices, candidate profiles, or maintenance schedules. Here is what patients can verify instead.
A destination longevity program is still health care abroad. Use this CDC-based checklist to assess the clinic, clinician, procedure, travel risks, records, insurance, and follow-up before paying.
Longevity Clinics World can help build a shortlist, but a directory listing is not accreditation. Use these checks for credentials, evidence, total cost, follow-up, and conflicts.
US longevity clinics are not outside regulation, but oversight is split. This map explains FDA product rules, state professional oversight, compounding, off-label care, and what patients can verify.
BBC reporting shows a market ranging from ordinary prevention to expensive tests and experimental treatments. This guide separates documented offers from proven health benefit.
Cash payment is not itself a warning sign, but selling tests or products can create conflicts. Use this evidence contract to separate the medical fee, product revenue, claims, and follow-up.
Longevity Docs promotes evidence, supervision, and traceable peptide supply. FDA records show why patients and clinics must verify the ingredient, compounder, lot, and regulatory pathway.
